SCHEMBL6287771

SCHEMBL6287771

COc1ccc(-c2cc3ncccc3[nH]2)cc1C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 5/20 0.47
SYK P43405 3/20 0.47
JAK2 O60674 1/20 0.44
CDC7 O00311 2/20 0.44
MKNK1 Q9BUB5 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
RIPK1 Q13546 1/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
CHEK2 O96017 1/20 0.41
CHUK O15111 1/20 0.41
INSR P06213 1/20 0.41
MAPK8 P45983 1/20 0.41
CAMKK2 Q96RR4 1/20 0.41
PKN1 Q16512 1/20 0.40
PKN2 Q16513 1/20 0.40
NPY5R Q15761 1/20 0.40
ALDH1A1 P00352 1/20 0.39
ATM Q13315 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286410 0.84 PARP1 (0.42) PARP1SYKJAK2CDC7MKNK1
SCHEMBL6279297 0.83 CCNB2 (0.56) RIPK1CHUKINSRMAPK8CAMKK2
SCHEMBL6286089 0.83 ACVR1 (0.42) PARP1SYKJAK2CDC7MKNK1
SCHEMBL6287778 0.82 RIPK1 (0.43) SYKRIPK1PTGDR2NPY5R
SCHEMBL6286700 0.81 RIPK1 (0.65) RIPK1
SCHEMBL6286918 0.77 PARP1 (0.47) PARP1SYKJAK2CDC7MKNK1
SCHEMBL6286151 0.77 IKBKB (0.47) PARP1JAK2CDC7MKNK1MKNK2
SCHEMBL6282531 0.77 IKBKB (0.47) PARP1JAK2CDC7MKNK1MKNK2
SCHEMBL6283126 0.76 PARP1 (0.52) PARP1SYKCDC7MKNK1MKNK2
SCHEMBL7101502 0.75 CCNB2 (0.44) RIPK1NPY5RALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014759-A1 6,5-Fused bicyclic heterocycles PICARD JOSEPH ARMAND (US) 2004-01-22 US claimed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP claimed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO claimed
US-6943174-B2 6,5-Fused bicyclic heterocycles WARNER-LAMBERT COMPANY (US) 2005-09-13 US disclosed
EP-1294718-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY LLC (US) 2003-03-26 EP disclosed
WO-2001096336-A2 6,5-FUSED BICYCLIC HETEROCYCLES WARNER-LAMBERT COMPANY (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014759-A1 6,5-Fused bicyclic heterocycles ALOX15, ALOX5, ALOX15B PARP1 1471/4885SYK 884/4885JAK2 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.